Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07599813 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study, sponsored by Apollo Therapeutics.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
NCT07599813: Recruiting Phase 2 study, sponsored by Apollo Therapeutics.
NCT07599813 is a Phase 2 study that is actively recruiting participants, run by Apollo Therapeutics. The registered enrollment target is 280 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07599813, a Phase 2 study, is actively recruiting participants, sponsored by Apollo Therapeutics.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
Study Summary
This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
Primary Outcome
An EASI score is a tool used to measure the extent (area) and severity of atopic eczema. The EASI utilizes area assessments that rate the four involved regions on a 0% to 100% scale for each region. The scores are added up for each of the four body regions (head, arms, trunk, and legs). For each of these components, the individual scores are added together to calculate the EASI score, which ranges from 0 to 72. The higher the EASI score, the more severe the AD.
Interventions
- DRUG Placebo
- DRUG Camoteskimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2026-05-28 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
What NCT07599813 shows while recruiting
NCT07599813 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (111% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07599813 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07599813 about?
NCT07599813 is a clinical study titled "A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis". This is a phase 2b, multicenter, randomized, double-blind, placebo-controlled study.
What is the current status of trial NCT07599813?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2026-05-28. Estimated completion is 2028-04-30.
What interventions are being tested in trial NCT07599813?
The interventions under investigation include: Placebo (DRUG), Camoteskimab (DRUG).
Who is sponsoring clinical trial NCT07599813?
This trial is sponsored by Apollo Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07599813's enrollment target sits among peer trials
280 196th of 2000 higher than 1,800 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI